LEQEMBI

This brand name is authorized in United States

Active ingredients

The drug LEQEMBI contains one active pharmaceutical ingredient (API):

1 Lecanemab UNII 12PYH0FTU9 - LECANEMAB

Lecanemab is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta. The accumulation of amyloid beta plaques in the brain is a defining pathophysiological feature of Alzheimer’s disease. Lecanemab reduces amyloid beta plaques, as evaluated in studies. Read about Lecanemab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
LEQEMBI Solution for injection	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
N06DX04		N Nervous system → N06 Psychoanaleptics → N06D Anti-dementia drugs → N06DX Other anti-dementia drugs
Discover more medicines within N06DX04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: US	FDA, National Drug Code	Identifier(s): 62856-212, 62856-215